A recent phase 1 multicenter study has demonstrated promising safety and efficacy results for a next-generation CAR-T cell therapy known as rapcabtagene autoleucel. This investigational treatment...
Research indicates that the next-generation CAR-T cell therapy, known as rapcabtagene autoleucel, demonstrates significant promise for patients suffering from refractory B-cell acute lymphoblastic leukemia. Data from...
